Our Promise to You

Guaranteed product quality, expert customer support

Our Promise to You

JVM-13

  • Specification
  • Recommended Products
Cat.No.
CSC-C3406
Description
Established from the peripheral blood of a male patient with B-prolymphocytic leukemia (PLL) at diagnosis; cell line was established by EBV-transformation during treatment with phorbol ester TPA
Species
Human
Source
chronic B cell leukemia
Recommended Medium
Culture Properties
suspension
Morphology
lymphoblastoid cells growing in clusters in suspension
Karyotype
Human hyperdiploid karyotype with 4% tetraploidy - 47(44-48)<2n>X, +8, -13, t(2;?)(q35;?), t(8;13)(p12;q13), t(8;?)(p12;?)
Quality Control
Mycoplasma: negative in DAPI, microbiological culture, RNA hybridization, PCR assays
Immunology: CD3 -, CD10 -, CD13 -, CD19 +, CD20 +, CD34 -, CD37 +, CD80 +, CD138 -, HLA-DR +, sm/cyIgM +, sm/cyIgG -, sm/cykappa -, sm/cylambda +
Viruses: ELISA: reverse
Storage and Shipping
Frozen with 70% medium, 20% FBS, 10% DMSO at about 3-5 x 10^6 cells/ampoule; ship in dry ice; store in liquid nitrogen
Citation Guidance
If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the PubMed ID of your paper to get a coupon.

For research use only. Not for any other purpose.

  • Background
  • Scientific Data
  • Q & A
  • Customer Review
  • Product Information Sheet

The JVM-13 cell line is a well-known cell line derived from the peripheral blood of a male patient diagnosed with B-lymphocytic leukemia (PLL). The cell line was established by the transformation of B-PLL cells using Epstein-Barr virus (EBV) during treatment with the phorbol ester TPA (12-O-tetradecanoylphorbol 13-acetate).

B-PLL is a rare and aggressive subtype of B-cell leukemia characterized by the proliferation of immature B lymphocytes with a prominent prolymphocytic morphology. It is considered a variant of chronic lymphocytic leukemia (CLL) with distinct clinical and pathological features. PLL typically presents with a high white blood cell count, splenomegaly (enlarged spleen), lymphadenopathy (enlarged lymph nodes), and bone marrow involvement. The establishment of the JVM-13 cell line has provided researchers with a valuable tool for studying the biology, pathogenesis, and therapeutic responses of B-PLL.

The transformation of the JVM-13 cells using EBV allows for their immortalization and long-term maintenance in cell culture. This provides researchers with a continuous and reliable supply of cells for experimental purposes. The use of TPA during the establishment of the cell line helps in promoting the growth and expansion of the transformed cells.

Shikonin Exert Antitumor Activity in JVM-13 Cells

Shikonin is a well-known antitumor substance that induces apoptosis, inhibits proliferation of cancer cells, and inhibits angiogenesis. The antitumor activity of shikonins in JVM-13, human B-PLL cells was explored. As shown in Fig. 1, derivatives of shikonin isobutyrylshikonin (IBS) and α-methylbutyrylshikonin (MBS) decreased the viability of JVM-13 cells in a dose-dependent manner. From a concentration of 110 μg/mL, both IBS and MBS reduced the viability of JVM-13 cells to 100% (Fig. 1).

As illustrated in Fig. 2, IBS- and MBS-induced apoptosis and the majority of JVM-13 cells were in or occurred during late apoptosis. Quantitative analysis of Bcl-2, Bax, Mcl-1, and Noxa molecules in JVM-13 cells strongly indicated apoptotic death of JVM-13 cells after treatment with MBS and IBS. Treatment of JVM-13 cells with IBS and MBS at a concentration of 2 µg/mL significantly attenuated the percentage of Mcl-1-expressing cells and significantly enhanced the percentage of cells that expressed the pro-apoptotic molecule Noxa, even at a lower concentration of 1 µg/mL (Fig. 2c). Analysis of Bax and Bcl-2 expression at mRNA levels also showed significant attenuation of Bcl-2 and enhancement of Bax mRNA levels after treatment of JVM-13 cells with IBS and MBS (Fig. 2d). The antiproliferative effects of testing molecules were evaluated by assessment of the Ki67 expression level in treated cells using flow cytometry. The percentage of Ki67-positive JVM-13 cells (Fig. 3) treated with IBS and MBS was significantly lower compared to untreated cells.

Fig. 1 Dose- and time-dependent cytotoxicity of IBS and MBS on the JVM-13 cell line. (Todorovic Z, et al., 2021)Fig. 1 Dose- and time-dependent cytotoxicity of IBS and MBS on the JVM-13 cell line. (Todorovic Z, et al., 2021)

Fig. 2 IBS and MBS induce apoptotic death of JVM-13 cells. (Todorovic Z, et al., 2021)Fig. 2 IBS and MBS induce apoptotic death of JVM-13 cells. (Todorovic Z, et al., 2021)

Fig. 3 IBS and MBS attenuate the expression of Ki67 in JVM-13 cells. (Todorovic Z, et al., 2021)Fig. 3 IBS and MBS attenuate the expression of Ki67 in JVM-13 cells. (Todorovic Z, et al., 2021)

Q:
What stain is used for biopsy?
A:

Gram stain of tissue biopsy test involves using crystal violet stain to test a sample of tissue taken from a biopsy. The Gram stain method can be used on almost any specimen. It is an excellent technique for making a general, basic identification of the type of bacteria in the sample.

Q:
Why are JVM-13 cells important in leukemia research?
A:

JVM-13 cells serve as a valuable model for studying B-prolymphocytic leukemia, providing insights into the molecular and cellular characteristics of this specific type of leukemia and offering opportunities to investigate potential therapeutic strategies.

Q:
How does the EBV-transformation during TPA treatment impact the behavior of JVM-13 cells?
A:

The EBV-transformation during TPA treatment plays a crucial role in the establishment of the JVM-13 cell line and may influence the cellular behavior, gene expression patterns, and response to certain treatments, making it an intriguing subject for research.

Q:
How can JVM-13 cells contribute to the development of targeted therapies for B-prolymphocytic leukemia?
A:

By studying JVM-13 cells, researchers can identify potential genetic aberrations, signaling pathways, and treatment responses specific to B-prolymphocytic leukemia, thus contributing to the development of targeted and personalized therapeutic interventions.

Ask a Question

Average Rating: 4.7    |    3 Scientist has reviewed this product

Ideal

Creative Bioarray's products are ideal for studying specific types of cancer, allowing for more targeted research.

06 Dec 2022


Ease of use

After sales services

Value for money


Highly recommend

We highly recommend Creative Bioarray for providing high-quality JVM-13 cells and excellent service.

01 Jan 2024


Ease of use

After sales services

Value for money


Valuable tools

Creative Bioarray's JVM-13 cell products have been instrumental in our research on B-prolymphocytic leukemia. These cells have provided valuable insights into the molecular and cellular characteristics of this disease, helping us identify potential therapeutic targets.

23 Sep 2023


Ease of use

After sales services

Value for money


Write your own review

Customer Support & Price Inquiry

Verification Code